Immortal Dragons, a forward-thinking longevity investment fund based in Singapore, is committed to accelerating radical life extension technologies. Unlike traditional investors who prioritize financial returns, Immortal Dragons focuses primarily on societal impact, underwriting cutting-edge startups engaged in transformative approaches such as whole-body replacement therapies, next-generation 3D bioprinting, advanced gene therapies, and innovative regulatory frameworks including special economic zones tailored for longevity biotech. Their investment philosophy challenges conventional aging paradigms by emphasizing the replacement of biological systems rather than mere repair, proposing a disruptive shift in combating aging.

This ethos is encapsulated by Founder Boyang Wang, who views aging as an engineering challenge solvable through technology and innovation. “Accepting aging and death as inevitable is a defeatist position. We believe that with the proper scientific breakthroughs and sustained advocacy, we can eradicate age-related diseases and significantly extend healthy human lifespan,” Wang asserts. Immortal Dragons thus operates not only as an investor but as an active participant in the longevity ecosystem through welfare grants, sponsorships, dissemination of knowledge via book translation and publishing, and hosting influential Chinese-language podcasts dedicated to longevity science.

ARDD 2025 promises a convergence of luminary figures, including Nobel laureates Morten Meldal and Michael Levitt, whose seminal contributions have revolutionized drug design and molecular modeling. Their pioneering work in molecular engineering and computational chemistry has laid the foundation for modern pharmacology and opened new avenues for creating targeted biomolecules with therapeutic potential. Their participation underscores the conference’s stature as an epicenter for multidisciplinary dialogue bridging fundamental research and clinical application in aging and drug discovery.

The conference embodies a unique fusion of academic excellence and industrial innovation, drawing leaders from leading pharmaceutical companies such as Novartis, Biogen, Eli Lilly, Regeneron, and Lundbeck. These industry giants actively engage with emerging research at ARDD, sharing insights into aging-related drug development pipelines and fostering collaborations aimed at translating molecular discoveries into viable medical interventions. The resulting synergies are instrumental in shaping the future trajectory of healthspan extension and age-associated disease amelioration.

A focal point at ARDD 2025 will be the special emphasis on Longevity Medicine, a novel discipline integrating clinical strategies and evidence-based approaches to healthy aging. This facet of the conference facilitates the exchange of clinical protocols, emerging therapies, and the application of artificial intelligence in medicine, targeting practitioners and researchers dedicated to preventive and regenerative healthcare. The inclusion of Longevity Medicine Day highlights an increasing recognition that extending lifespan necessitates a holistic approach encompassing molecular biology, pharmacology, and patient-centered clinical practice.

Moreover, ARDD serves as a melting pot for dialogues on technological innovation in longevity. Emerging tools such as AI-driven drug discovery platforms exemplify how computational methodologies are accelerating identification and optimization of molecules capable of modulating aging pathways. The integration of AI with traditional biopharmaceutical research is paving the way for unprecedented efficiency in understanding complex biological systems, unlocking therapeutic targets that were previously intractable.

The conference’s organizers stress the importance of grounding longevity science in rigorous, reproducible research. Professor Evelyne Bischof, organizer of the Longevity Medicine Days, emphasizes that the presence of Nobel laureates in the scientific roster highlights a commitment towards validated scientific excellence. “Our goal is to promote longevity interventions supported by robust evidence, ensuring that advancements in this burgeoning field meet the highest standards of scientific integrity,” she states.

ARDD’s role extends beyond fostering dialogue; it directly contributes to building an international collaborative network among academia, industry, and investors. This ecosystem is critical for overcoming the multifaceted challenges posed by aging—a complex biological phenomenon characterized by molecular damage accumulation, systemic decline, and increased vulnerability to diseases. Through partnerships catalyzed at ARDD, novel therapeutics designed to target fundamental aging mechanisms, such as senescence, proteostasis dysregulation, and mitochondrial dysfunction, are steadily moving from bench to bedside.

Recent years have witnessed accelerating momentum in the aging research arena, with substantial investments channeled towards pharmacological agents like senolytics, NAD+ precursors, and epigenetic modulators. ARDD serves as the principal stage for unveiling such advancements and engaging stakeholders in interactive sessions aimed at refining translational strategies. The conference also addresses regulatory, ethical, and societal considerations inherent in extending human healthspan, ensuring that scientific breakthroughs translate responsibly into clinical applications.

Importantly, the collaboration with Immortal Dragons adds a visionary partner focused on enabling ambitious, so-called “moonshot” projects which challenge established scientific dogmas. Their portfolio includes ventures exploring radical rejuvenation techniques and systemic replacement approaches aimed at restoring youthful biological functions. By nurturing such ventures, Immortal Dragons catalyzes an ecosystem that not only innovates incrementally but also dares to redefine the boundaries of human longevity.

In sum, ARDD 2025 presents a rare opportunity to witness and contribute to an accelerating confluence of science, technology, and medicine aimed at confronting one of humanity’s most profound challenges. Supported by a diverse constellation of thought leaders, investors, and industry titans, the event offers unparalleled insight into the future of aging research and drug discovery. As the world grapples with demographic shifts towards older populations, ARDD’s mission resonates with urgency and hope—a testament to the transformative potential of collaborative innovation in extending healthy lifespan.

For media inquiries and further information, please contact the organizing team at ardd@pharma.ai or reach out directly to Dr. Morten Scheibye-Knudsen of the University of Copenhagen at mscheibye@sund.ku.dk.

Subject of Research: Aging biology, longevity biotechnology, radical life extension, drug discovery targeting aging

Article Title: University of Copenhagen Welcomes Immortal Dragons as Tier 4 Sponsor for ARDD 2025 to Accelerate Radical Longevity Innovations

News Publication Date: Information not provided

Web References:

• University of Copenhagen: https://www.ku.dk/english/
• Aging Research & Drug Discovery Meeting: https://agingpharma.org/
• Immortal Dragons: Not provided directly, inferred as longevity investment fund headquartered in Singapore

Image Credits: ARDD (Aging Research and Drug Discovery Conference)

Keywords: Health and medicine, Aging research, Longevity, Drug discovery, Biopharmaceuticals, Radical life extension, Whole-body replacement, Gene therapy, 3D bioprinting, Artificial intelligence, Longevity medicine, Nobel laureates

ARDD 2025 positions itself at the confluence of pioneering longevity science and practical impact on human healthspan, embodying the vision of Mitra Bio’s CEO, Dr. Shakiba Kaveh. Mitra Bio has devoted the past five years to advancing the field of skin aging through innovative, non-invasive epigenetic testing methodologies. Their proprietary tape-strip sampling combined with next-generation sequencing revolutionizes traditional biopsy approaches, enabling rapid, painless, and high-resolution epigenetic profiling. This advancement holds exceptional promise for dermatological applications, medical devices, and pharmaceutical research, offering a transformative tool for understanding the molecular underpinnings of skin aging and translating insights into clinically relevant interventions.

ARDD has experienced exponential growth, establishing itself as an exclusive nexus where leading scientists, biotech innovators, venture capitalists, and pharmaceutical executives converge. The conference fosters robust scientific exchange, collaborative partnerships, and exposure to groundbreaking research innovations that are redefining aging as a modifiable biological process. Each year, the gathering spotlights emergent themes from molecular gerontology, cellular senescence, regenerative medicine, to AI-driven drug discovery, reflecting the escalating interdisciplinarity in longevity sciences.

The excitement for ARDD 2025 is further amplified by the participation of Nobel Laureates Professor Morten Meldal and Professor Michael Levitt. Their groundbreaking contributions to molecular design and protein modelling have catalyzed drug discovery and computational biology. According to Professor Morten Scheibye-Knudsen from the University of Copenhagen, their presence will provide invaluable insights and enrich the scientific dialogue at ARDD. The convergence of Nobel-caliber intellects with leading industry practitioners underscores the conference’s unparalleled prominence and ambition.

Professor Daniela Bakula echoes the anticipation surrounding these illustrious guests, emphasizing that their seminal work has reshaped contemporary drug discovery paradigms. Their engagement promises to elevate the conference discourse, inspiring innovative approaches in aging research and pharmaceutical development. These interactions between Nobel laureates, academic leaders, and industry pioneers typify ARDD’s commitment to fostering a vibrant ecosystem dedicated to longevity biotechnology.

Over the past twelve years, ARDD has evolved into the quintessential platform promoting cross-sectoral dialogue among academia, pharmaceutical giants, startups, and investors. The forum’s unique capacity to unite these stakeholders accelerates the translation of fundamental aging research into viable therapeutics that extend healthy human lifespan. In 2025, the conference will pioneer novel initiatives, including a dedicated Longevity Medicine Day, aimed at clinicians and health practitioners focusing on evidence-based interventions for age-associated diseases.

The critical importance of ARDD is reflected in its ability to showcase pharmaceutical industry leaders such as Novartis, Biogen, Eli Lilly, and others who actively engage in aging research. Their presence at previous meetings solidifies ARDD as the central venue for unveiling next-generation therapeutics targeting aging mechanisms. The integration of cutting-edge AI applications in drug discovery further distinguishes ARDD, with industry experts exploring artificial intelligence as a pivotal tool in accelerating candidate drug identification, personalized treatment regimens, and clinical trial design.

Longevity research at ARDD highlights the shift from viewing aging solely as an inexorable decline to recognizing it as a malleable biological process amenable to intervention. This paradigm shift opens unprecedented avenues for drug development aimed at not only extending lifespan but more importantly enhancing healthspan. The inclusion of Longevity Medicine Day underscores the translation of benchside discoveries to bedside applications, offering clinicians insights on novel diagnostics, biomarkers, and therapeutic strategies to manage aging-related pathologies with scientific rigor.

Mitra Bio’s sponsorship symbolizes a confluence of research innovation and entrepreneurial vision. Their skin epigenetic testing platform exemplifies the intersection of omics technologies, bioinformatics, and clinical utility—a triad central to next-generation precision medicine approaches in aging. By enabling non-invasive monitoring of biological aging in easily accessible tissues such as skin, Mitra Bio paves the way for earlier intervention, personalized skincare, and improved patient care paradigms, reflecting a broader trend embracing digital aging biomarkers.

The integrative nature of ARDD and the participation of companies like Mitra Bio emphasize the dynamic expansion and maturation of the aging research community. The conference strives to bridge gaps between mechanistic biological insights, technological advancements, clinical translation, and commercial scalability. This holistic approach is essential to surmount challenges inherent in aging biology, including complexity, heterogeneity, and multifactorial etiologies.

In summary, ARDD 2025 promises to be a landmark event within the longevity research landscape. It will bring together Nobel Prize-winning scientists, industry thought leaders, innovative startups, and healthcare professionals under one roof to explore the frontiers of aging science and drug discovery. With a robust agenda featuring multidisciplinary scientific sessions, collaborative workshops, and industry showcases, ARDD stands as a beacon for advancing the future of healthy longevity medicine.

For media inquiries, further information, and interview requests related to ARDD 2025 or Mitra Bio, interested parties may contact ardd@pharma.ai or reach out directly to Mitra Bio media representative Jay Yeung at jay@mitrabio.tech. Additional information about Mitra Bio’s novel skin epigenetic testing approach can be found at mitrabio.tech and their LinkedIn profile.

Image Credits: Mitra Bio

Keywords: Health and medicine, aging research, drug discovery, longevity science, skin epigenetics, non-invasive testing, molecular biology, biotechnology, pharmaceutical industry, artificial intelligence, clinical interventions, precision medicine